Ensign Peak Advisors
CYTK icon

Ensign Peak Advisors’s Cytokinetics CYTK Stock Holding History

Ensign Peak Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$634K Buy
7,446
+150
+2% +$10.8K ﹤0.01% 922
2026
Q1 		$481K Hold
7,296
– – ﹤0.01% 969
2025
Q4 		$464K Sell
7,296
-13,200
-64% -$821K ﹤0.01% 977
2025
Q3 		$1.13M Sell
20,496
-183,450
-90% -$7.56M ﹤0.01% 979
2025
Q2 		$6.74M Buy
203,946
+172,150
+541% +$5.99M 0.01% 575
2025
Q1 		$1.28M Sell
31,796
-265,039
-89% -$12.2M ﹤0.01% 1114
2024
Q4 		$14M Sell
296,835
-165,001
-36% -$8.57M 0.02% 388
2024
Q3 		$24.4M Sell
461,836
-1,595
-0.3% -$88.9K 0.04% 289
2024
Q2 		$25.1M Buy
463,431
+39,172
+9% +$2.36M 0.05% 271
2024
Q1 		$29.7M Sell
424,259
-1,604
-0.4% -$124K 0.05% 253
2023
Q4 		$35.6M Hold
425,863
– – 0.07% 231
2023
Q3 		$12.5M Buy
425,863
+74,694
+21% +$2.49M 0.03% 336
2023
Q2 		$11.5M Hold
351,169
– – 0.02% 387
2023
Q1 		$12.4M Buy
351,169
+8,400
+2% +$343K 0.03% 369
2022
Q4 		$15.7M Buy
342,769
+59,400
+21% +$2.56M 0.04% 332
2022
Q3 		$13.7M Buy
283,369
+45,600
+19% +$2.19M 0.03% 321
2022
Q2 		$9.34M Buy
237,769
+69,904
+42% +$2.81M 0.02% 396
2022
Q1 		$6.18M Buy
167,865
+9,960
+6% +$354K 0.01% 528
2021
Q4 		$7.2M Sell
157,905
-40,650
-20% -$1.57M 0.01% 560
2021
Q3 		$7.1M Sell
198,555
-4,000
-2% -$118K 0.01% 519
2021
Q2 		$4.01M Buy
202,555
+37,010
+22% +$869K 0.01% 740
2021
Q1 		$3.85M Buy
165,545
+91,145
+123% +$1.95M 0.01% 743
2020
Q4 		$1.55M Sell
74,400
-49,022
-40% -$896K ﹤0.01% 1203
2020
Q3 		$2.67M Buy
123,422
+49,022
+66% +$1.15M 0.01% 822
2020
Q2 		$1.75M Hold
74,400
– – ﹤0.01% 1044
2020
Q1 		$877K Buy
74,400
+8,500
+13% +$108K ﹤0.01% 1216
2019
Q4 		$699K Buy
+65,900
New +$677K ﹤0.01% 1456

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's CYTK Position: Q2 2026 in Review

Ensign Peak Advisors increased its Cytokinetics (CYTK) stake by 2.1% in Q2 2026, buying an estimated $10.8K and bringing the position to 7,446 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #922.

Ensign Peak Advisors first reported a position in CYTK in Q4 2019 and has held it in 27 quarters since. The position peaked at $35.6M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Ensign Peak Advisors held 7,446 shares of Cytokinetics worth $634K as of Q2 2026.
  • Ensign Peak Advisors bought 150 Cytokinetics shares in Q2 2026, an estimated $10.8K.
  • Cytokinetics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #922 holding.
  • Ensign Peak Advisors first reported a position in Cytokinetics in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Cytokinetics position peaked at $35.6M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.